Anti-diabetic drugs: a novel therapeutic approach against cisplatin-induced kidney injury, a mechanistic review of preclinical studies.
Review
Overview
abstract
Cisplatin (Cis) is a potent anti-cancer agent with limited clinical application due to severe adverse effects, including nephrotoxicity. Acute kidney injury (AKI) is the most frequently observed type of nephrotoxicity following Cis administration. Inflammation, oxidative stress, direct cell toxicity, and immune cell recruitment are the primary pathophysiological factors influencing Cis-induced AKI. Anti-diabetic medications have demonstrated regulatory effects on various signaling pathways and chemokines associated with Cis-induced AKI, such as AMP-activated protein kinase (AMPK) and nuclear factor erythroid 2-related factor 2 (Nrf2). We hypothesized that these agents might offer novel insights into the modulation of Cis-induced kidney injury. In this review, we explored scientific databases for original English studies on the effects of anti-diabetic medications on Cis-induced nephrotoxicity. Biguanides, thiazolidinediones, dipeptidyl peptidase 4 inhibitors (DPP4Is), sodium-glucose cotransporter inhibitors (SGLT2Is), and sulfonylureas exerted beneficial effects against Cis-induced kidney injury in preclinical studies. They reduced inflammation and lowered creatinine, blood urea nitrogen levels, and injury scores. Furthermore, these agents alleviated oxidative stress and modified key pathways related to apoptosis and autophagy, including nuclear factor kappa B (NF-κB), the mammalian target of rapamycin (mTOR), and AMPK. They can provide alternative strategies for reducing cisplatin-induced kidney toxicity. However, further clinical investigations are needed to translate this potential into clinical practice. Appropriate dosages and possible alterations in pharmacokinetic behavior should be evaluated.
